Keegan S. Cooke
0000-0002-8509-1241
Publication & Citation Trends
Publications
0 total
Abstract 7086: Preclinical characterization of a potent and selective Werner helicase (WRN) inhibitor with activity in low-TA repeat microsatellite instability-high (MSI-H) cancers
Cited by 0
Semantic Scholar
1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models OA
Cited by 1
Semantic Scholar
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity Against Prostate Cancer.
Cited by 35
Semantic Scholar
OncoVEXmGM-CSFexpands tumor antigen-specific CD8+ T-cell response in preclinical models OA
Cited by 13
Semantic Scholar
Immunotherapeutic targeting and PET imaging of DLL3 in small cell neuroendocrine prostate cancer. OA
Cited by 41
Semantic Scholar
Characterization of an Anti-CD70 Half-Life Extended Bispecific T Cell Engager (HLE-BiTE) and Associated On-Target Toxicity in Cynomolgus Monkeys. OA
Cited by 10
Semantic Scholar
P15.01 AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer OA
Cited by 3
Semantic Scholar
Abstract 1586: Oncolytic virus HSV-1/ICP34.5-/ICP47-/mFLT3L/mIL12 promotes systemic anti-tumor responses and cooperates with immuno-modulatory agents in multiple mouse syngeneic tumor models
Cited by 1
Semantic Scholar
Research Topics
Lung Cancer Research Studies
(80)
Immunotherapy and Immune Responses
(45)
Neuroendocrine Tumor Research Advances
(44)
CAR-T cell therapy research
(44)
Monoclonal and Polyclonal Antibodies Research
(39)
Affiliations
University of Sydney
University of Minnesota
Amgen (United States)
University of Minnesota System
Cork University Hospital